Emad Ibrahim

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 78 citations · Full text

Nivolumab Versus Docetaxel, Medicine, Pharmacology +7

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Ignace Vergote, Agustin A. García, John P. Micha et al. · Journal of Clinical Oncology · 2013 · 52 citations · Full text

Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy

James Wang, Kyle A. Udd, Aleksandra Vidisheva et al. · Supportive Care in Cancer · 2016 · 40 citations

Hematology, Pathology, Neurology +6

Long‐Term Treatment with Glucocorticoids Increases Synthesis and Stability of Junctional Acetylcholine Receptors on Innervated Cultured Human Muscle

Serge Braun, Valerie Askanas, W. King Engel et al. · Journal of Neurochemistry · 1993 · 31 citations